Ireland
--:--IST
Recruiting Observational

Collection of Stool From Healthy Donors for the ex Vivo Study of Shifts of Microbiome Induced by Dairy Phages and Antibiotics: a Model of Bacteria/Host Interaction (DAIRY-SHAPE)

NCT07212400 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-10-16
Last updated
2026-01-13

Condition(s) studied

General Population (no Specific Condition or Disease)

Study summary

The gut microbiota plays a crucial role in health through its involvement in pathogen defense, immune regulation, and nutrient digestion. Microbiota diversity is essential to maintain these functions, and disturbances caused by antibiotic intake or extreme diets can lead to an imbalance (dysbiosis), which is often described as being implicated in numerous diseases as well as in the proliferation of antibiotic-resistant pathogens.

The microbiota is defined as the community of microorganisms inhabiting the intestine, including bacteria, viruses, and bacteriophages (phages). These phages, through their ability to destroy the bacteria they infect, play an important role in regulating bacterial populations and could therefore be essential for restoring balance and diversity in the gut.

Probiotics, foods that support the microbiota such as dairy products, are of particular interest because the specific interactions between phages and bacteria within these food microbiomes could stimulate microbiota restoration.

This study aims to evaluate the effectiveness of phage-based functional foods in restoring intestinal homeostasis and, by extension, improving human health. It will serve as a model to examine how phages present in foods, particularly dairy products, influence gut microbial diversity and to determine whether these phages promote recovery after antibiotic-induced disturbances.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥ 18 years and ≤ 60 years * Varied and balanced omnivorous diet Exclusion Criteria: * Vegetarian, vegan, or restrictive diet * Use of medications (antibiotics, anti-inflammatory drugs, immunosuppressants, and/or probiotics, prebiotics, or synbiotics), either as drugs or dietary supplements, within the 3 months prior to sample collection * Pregnant and/or breastfeeding women * Presence of an acute or chronic disease (gastrointestinal, metabolic, immune, or inflammatory), diagnosed or suspected * Colonoscopy within the past 3 months * Known food allergy or intolerance (e.g., gluten, lactose, FODMAPs) that may alter the usual diet and/or microbiota composition * Individuals under legal protection (guardianship, trusteeship, etc.)

Primary outcome measure(s)

  • Primary Outcome — Up to 3 years
    To assess the ability of dairy phages to modulate the intestinal microbiota in vitro using a fermenter system, in the presence and absence of antibiotics.
  • Secondary Outcome — Up to 3 years
    To monitor the temporal dynamics of the intestinal microbiota following the addition of dairy phages and antibiotics.

Trial sites (1)

FacilityCityRegionStatus
Metagenopolis Jouy-en-Josas France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07212400 on ClinicalTrials.gov ↗ ← All trials in France